Ocular Therapeutix announces over 300 subjects randomized in SOL-1
In This Article:
Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025.
Don't Miss our Black Friday Offers:
-
Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUL:
Terms and Privacy Policy